CDH1 and prostate cancer: According to the results of chromatin immunoprecipitation (ChIP) assays, miR-N5 decreases CBP, a component of KATs, and mediates H3K56 deacetylation at the promoter of E-cadherin to suppress its expression in prostate cancer [33].